Table of contents


On 27 June 2016, orphan designation (EU/3/16/1680) was granted by the European Commission to Chugai Pharma Europe Ltd, UK, for humanised anti-IL-6 receptor monoclonal antibody (also known as SA237) for the treatment of neuromyelitis optica spectrum disorders.

The sponsorship was transferred to Chugai Pharma France, France, in January 2019.

Key facts

Active substance
Humanised anti-IL-6 receptor monoclonal antibody
Disease / condition
Treatment of neuromyelitis optica spectrum disorders
Date of first decision
EU designation number

Sponsor's contact details

Chugai Pharma France
100-101 Quartier Boieldieu
Tour Franklin
Arche Sud
92042 Paris la Défense Cedex
Tel. +33 1 56 37 05 29

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating